Meeting
2013 Gastrointestinal Cancers Symposium
Racial disparities and the outcome of metastatic (met) colorectal cancer (CRC).
Authors
Afsaneh Barzi
University of Southern California Norris Comprehen
Afsaneh Barzi , Maryam Shabihkhani , Steven Yu , Dongyun Yang , Lingyun Ji , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr373)
DOI
10.1200/jco.2013.31.4_suppl.373
Abstract #
373
Poster Bd #
A41
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
QoL analysis: A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer—The C-cubed study.
First Author: Shingo Noura
Poster
2020 Gastrointestinal Cancers Symposium
Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy.
First Author: Ying Liu
Poster
2020 Gastrointestinal Cancers Symposium
First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).
First Author: Zev A. Wainberg
Poster
2019 ASCO Annual Meeting
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
First Author: Ronnie Shapira-Frommer